DMAC · DiaMedica Therapeutics Inc.
Market Cap
$364.00M
Shares
53.93M
DMAC metrics
52 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$6.75
Market cap
$364.00M
Price action
19 metricsPrice change (1W)
+5.6%
Price change (30D)
+1.5%
Price change (3M)
+19.7%
Price change (6M)
-12.5%
Price change (YTD)
-15.2%
Price change (1Y)
+25.7%
Trailing year
Price change (5Y)
+64.6%
52-week high
$9.39
52-week low
$5.33
Change from 52-week high
-28.1%
Change from 52-week low
+26.6%
Annualized volatility
59.1%
Beta
1.5
RSI (14D)
52.6
Price vs SMA 50
-2.3%
Price vs SMA 200
-6.3%
Avg volume (3M)
192,642
Relative volume
1.0
Average dollar volume
$1.30M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
53.93M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
9.5
reciprocal yield 10.5%
FCF yield
-8.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-11
Profitability
9 metricsGross margin
—
Operating margin
-1,352.2%
Trailing 12 months
Net margin
-1,146.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$39.23M
Net income (TTM)
−$37.54M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-97.9%
Return on assets
-83.4%
Debt / equity
—
Current ratio
6.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$31.54M
Quick ratio
6.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$43.50M
Latest balance sheet
Cash & equivalents
$5.13M
Total assets
$45.00M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$31.51M
Capital expenditures (TTM)
$33,000
R&D (TTM)
$29.28M
SG&A (TTM)
—
Stock compensation (TTM)
$4.15M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
88
13F filer change QoQ
-11
Institutional ownership
23.1%
Short interest
3 metricsShort interest
9.9%
Latest settlement · 37.9 days to cover
Days to cover
37.9d
Short-squeeze score
75 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—